Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer’s disease (AD) is being presented in a Poster Presentation at the 2026 Alzheimer’s Association International Conference ® (AAIC ® ), being held July 12-15, 2026 in London, United Kingdom and online. Results presented in “ Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using Free Water MRI ” provide support for a clinically relevant and durable anti-inflammatory mechanism of action of laromestrocel in gray and white matter and indicate potential bloo.